公司资料
Seagen 股价、新闻与催化剂
- 股票代码:
- SGEN
- 交易所:
- NASDAQ
- 行业:
- Antibody Drugs, ADCs
- 所在地:
- United States
股价为何变动
Current closing-price context is not available for SGEN.
公司概览
业务概览
Seagen was a biotechnology company focused on antibody-drug conjugates and oncology before being acquired by Pfizer. Its identity was tied to cancer therapeutics and the broader validation of ADC technology.
所在地与行业分类
Seagen was headquartered in the United States and listed on NASDAQ before its acquisition. It sat in oncology biotechnology with a strong U.S. commercial and development presence.
商业模式特征
The business depended on oncology product sales, ADC innovation, and the ability to expand the reach of its platform through development and partnership activity. Investors focused on clinical data, label expansion, and the strategic value of its ADC franchise.
生物医药行业定位
Seagen was one of the most important ADC-focused biotech companies of its time. It occupied a high-catalyst position because oncology readouts and platform validation directly influenced the stock.
未来催化剂
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。